Physician profile
Hari P Singh
NPI 1396709267
$9,343.84
in general payments reported to CMS, 2019-2025
38 companies · $1,737 in 2025
The $1,737 reported for 2025 was more than what 76% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,191 · 2020: $1,010 · 2021: $1,184 · 2022: $1,311 · 2023: $1,406 · 2024: $1,506 · 2025: $1,737.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,385 · Education: $184 · Gift: $79.69.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,385.26 |
| Education | $183.66 |
| Gift | $79.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,637.20 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Janssen Biotech, INC. | $1,297.27 | 2019-2025 | Tremfya, Stelara, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,111.42 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Celgene Corporation | $671.04 | 2021-2024 | Zeposia |
| Pfizer INC. | $495.68 | 2019-2025 | |
| Braintree Laboratories, INC. | $486.55 | 2019-2023 | Sutab |
| Takeda Pharmaceuticals U.S.A., INC. | $284.64 | 2021-2025 | Entyvio, Eohilia |
| Lilly USA, LLC | $284.30 | 2023-2025 | Omvoh |
| Ipsen Biopharmaceuticals, INC | $268.21 | 2024-2025 | Iqirvo, Bylvay |
| Phathom Pharmaceuticals, INC. | $197.37 | 2024-2025 | Voquezna |
| Redhill Biopharma INC. | $174.02 | 2020-2022 | |
| Gilead Sciences, INC. | $139.06 | 2019-2025 | |
| Vivus LLC | $136.80 | 2021-2025 | Pancreaze, Qsymia |
| Ardelyx, INC. | $134.53 | 2022-2025 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $102.47 | 2020-2022 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hari Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.